2023 World Conference on Lung Cancer (Posters)-P1.12. APC-1, A Novel Aptamer-Cisplatin Conjugate, Exhibits Promising Anti-tumor Effect in Lung Cancer

P1.12. APC-1, A Novel Aptamer-Cisplatin Conjugate, Exhibits Promising Anti-tumor Effect in Lung Cancer - PDF(Slides)

Pdf Summary

Researchers have developed a novel aptamer-cisplatin conjugate, called APC-1, that shows promising anti-tumor effects in lung cancer. Cisplatin is commonly used in chemotherapy for lung cancer, but it has limited effectiveness and is known to cause neurotoxicity. The researchers found that APC-1 had a superior tumor-suppressive effect compared to cisplatin in lung cancer models. Additionally, APC-1 showed identical tumor suppression to cisplatin but did not cause significant weight loss in mice. The researchers also discovered that the aptamer sequence of APC-1 was detectable in both the plasma and cerebrospinal fluid, suggesting it can penetrate the blood-brain barrier and target lung cancer with leptomeningeal metastasis. This is significant because current treatments for leptomeningeal metastasis are inadequate. The researchers believe that APC-1 has the potential to be an effective treatment option for lung cancer and could potentially improve outcomes for patients with leptomeningeal metastasis. Further research and clinical trials are needed to confirm these findings and evaluate the safety and efficacy of APC-1 in humans.

Asset Subtitle

Emily Lin

Meta Tag

Speaker Emily Lin

Topic Tumor Biology: Translational Biology - Translational Therapeutics

Keywords

aptamer-cisplatin conjugate

APC-1

anti-tumor effects

lung cancer

chemotherapy

neurotoxicity

tumor-suppressive effect

weight loss

blood-brain barrier

leptomeningeal metastasis